Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/IIa Clinical Trial of AsiDNA in Combination with Chemotherapy (Tumor-DNA Damaging Agent) for the Treatment of Solid Tumors

Trial Profile

A Phase Ib/IIa Clinical Trial of AsiDNA in Combination with Chemotherapy (Tumor-DNA Damaging Agent) for the Treatment of Solid Tumors

Planning
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs AsiDNA (Primary) ; Antineoplastics
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Onxeo SA
  • Most Recent Events

    • 25 Oct 2018 According to an Onxeo SA media release, Onxeo plans to start this study as soon as H1 2019.
    • 03 Aug 2018 New trial record
    • 27 Jul 2018 According to an Onxeo SA media release, this trial is expected to start early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top